No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
220 |
4. Check minimum number of eventsNone |
220 |
5. Include endpointsNone |
220 |
6. Filter based on genotype QC (FinnGen only) |
196 |
Control definitions (FinnGen only)
- Control exclude
- G6_NERPLEX
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Disorders of other and unspecified cranial nerves
based on the number of shared cases.
Similar with more cases:
- Nerve, nerve root and plexus disorders
- Neurological diseases
- Neurological diseases, wide definition
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1570 | 846 | 707 |
| Only index persons | 1256 | 694 | 562 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.03 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 52.04 | 52.68 | 50.94 |
| Only index persons | 49.33 | 50.00 | 48.49 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 196 | 99 | 97 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.04 |
| Median age at first event (years) | 47.34 | 43.06 | 51.70 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 204
- Matched controls
- 2040
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G52.8
ICD-10 Finland
Disorders of other specified cranial nerves
+∞
85.6
76
*
G52.9
ICD-10 Finland
Cranial nerve disorder, unspecified
+∞
78.3
70
*
35608
ICD-8 Finland
Other diseases of cranial nerves, Alterius nervi
+∞
34.3
32
*
G51.0
ICD-10 Finland
Bell palsy
+∞
26.6
25
*
N03AX16
ATC
[U] pregabalin
3.9
17.6
68
230
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
5.6
17.6
37
77
35609
ICD-8 Finland
Other diseases of cranial nerves, Unspecified
+∞
16.9
16
*
TAB00
NOMESCO Finland
Lumbar puncture
6.8
15.0
25
41
H49.0
ICD-10 Finland
Third [oculomotor] nerve palsy
53.6
13.0
15
*
N06AA09
ATC
amitriptyline; systemic
4.4
11.5
31
79
R51.80
ICD-10 Finland
Headache
3.3
10.8
49
179
3529X
ICD-9 Finland
Disorders of other cranial nerves, Unspecified disorder of cranial nerves
+∞
10.5
10
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
4.2
10.3
30
81
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.8
10.3
34
101
AA1AD
NOMESCO Finland
CT of head and brain
2.6
9.4
77
386
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
19.7
9.1
13
7
N03AE01
ATC
clonazepam; systemic
5.0
9.0
20
43
H53.2
ICD-10 Finland
Diplopia
7.0
8.8
21
33
ACC51
NOMESCO Finland
Release of median nerve
93.8
8.5
9
*
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
3.1
8.2
39
145
N02AX02
ATC
tramadol; systemic, rectal
2.3
8.0
99
588
J38.0
ICD-10 Finland
Paralysis of vocal cords and larynx
11.5
7.4
13
12
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
6.5
7.3
18
30
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
3.1
6.7
30
108
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.1
6.6
109
713
H02AB06
ATC
prednisolone; systemic
2.1
6.4
104
674
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.2
6.3
81
478
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.1
6.1
81
483
N03AF01
ATC
carbamazepine; oral, rectal
4.1
6.1
17
44
N02BF02
ATC
pregabalin; oral
3.5
6.0
21
64
A06AC01
ATC
ispaghula (psylla seeds); oral
2.2
6.0
64
350
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
124
767
2.57
9.75
8.6
6.6
1.22
1.21
mmol/l
0.55
113
702
131
838
2.57
9.49
10.2
7.6
1.22
1.21
mmol/l
1.20
118
721
73
398
2.30
7.06
2.8
2.3
—
—
—
0
0
165
1287
2.48
6.23
10.8
8.0
84.04
78.11
u/l
0.60
156
1218
112
751
2.09
6.21
3.0
2.6
78.06
76.85
nmol/l
0.15
104
672
111
743
2.08
6.17
3.4
3.0
—
—
estimate
—
0
0
43
202
2.43
5.72
4.7
4.9
32.33
31.83
%
0.10
33
129
54
285
2.22
5.48
1.8
1.7
1094.83
1177.35
nmol/l
0.21
40
219
51
269
2.19
5.16
3.6
1.8
29.09
29.18
s
0.03
51
264
106
736
1.92
4.95
2.5
2.1
99.06
96.81
pmol/l
0.15
59
373
28
119
2.57
4.57
1.9
1.7
—
—
—
0
0
70
434
1.93
4.51
2.8
2.2
2.74
2.85
mg/l
0.19
55
378
90
606
1.87
4.50
4.6
3.5
2.37
2.35
mmol/l
0.83
84
558
36
185
2.15
3.83
10.5
10.6
1.78
0.60
mmol/l
0.81
29
148
24
104
2.48
3.76
2.0
1.7
—
—
—
0
0
10
20
5.20
3.74
1.2
1.1
—
—
—
0
0
74
494
1.78
3.65
1.8
1.7
24.48
20.96
nmol/l
0.82
67
413
137
1096
1.76
3.50
7.4
4.8
1350.17
263.28
e6/l
—
6
25
90
643
1.72
3.46
5.2
3.9
191.03
37.21
ng/l
0.77
69
456
9
18
5.18
3.41
1.2
1.1
—
—
—
0
0
13
38
3.58
3.38
1.8
1.3
—
—
—
0
0
8
15
5.50
3.22
1.3
1.0
—
—
—
0
0
122
964
1.66
3.09
12.1
10.1
4.13
4.04
e9/l
0.15
100
837
46
279
1.84
3.06
2.1
2.0
—
—
—
0
0
73
509
1.68
2.99
3.5
2.6
56.66
75.54
u/l
0.77
68
469
18
76
2.50
2.99
1.6
1.2
—
—
—
0
0
99
749
1.63
2.93
4.4
2.9
119.96
113.54
ug/l
0.16
89
701
7
13
5.53
2.89
1.6
1.2
1.62
2.03
mmol/l
—
7
13
56
372
1.70
2.71
2.1
1.7
0.98
1.42
mg/l
0.86
48
306
76
547
1.62
2.70
3.2
3.1
3773.20
1296.91
ng/l
1.21
64
473
46
290
1.76
2.68
4.9
2.9
0.78
0.80
e6/l
0.04
28
140
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
13
49
2.77
2.68
1.6
2.5
0.27
0.40
iu/ml
—
6
25
14
55
2.66
2.68
1.6
1.3
—
—
—
0
0
27
144
2.01
2.61
4.9
2.8
4.63
4.23
kpa
0.51
27
139
6
11
5.58
2.56
1.2
1.0
—
—
—
0
0
39
239
1.78
2.50
7.9
5.9
1.02
1.04
mmol/l
0.13
34
215
83
621
1.57
2.47
5.4
3.3
—
—
—
0
0
51
342
1.65
2.36
1.5
1.8
419.72
14035532.69
pmol/l
0.50
46
285
77
572
1.56
2.34
4.8
3.7
13.21
10.14
mg/mmol
0.26
54
354
34
206
1.78
2.26
1.9
1.8
—
—
—
0
0
33
199
1.79
2.23
1.8
1.8
—
—
—
0
0
23
123
1.98
2.22
1.2
1.4
—
—
—
0
0
29
170
1.82
2.14
5.5
3.7
5.57
5.64
kpa
0.22
29
165
42
276
1.66
2.10
5.6
3.1
1.96
1.76
e6/l
0.08
23
127
26
150
1.84
2.02
9.0
7.4
9.80
9.81
mmol/l
0.00
26
143
13
57
2.37
2.02
1.2
1.3
—
—
—
0
0
67
500
1.51
1.94
4.7
3.2
0.33
0.48
e6/l
0.35
52
351
11
46
2.47
1.88
1.1
1.8
—
—
—
0
0
39
259
1.63
1.87
1.3
1.3
1.29
10.45
u/ml
1.17
15
93
46
319
1.57
1.85
4.7
3.8
57.26
228.48
ng/l
1.12
40
258
129
1102
1.46
1.84
4.3
3.1
48.12
43.46
u/l
0.40
118
1040
19
102
1.95
1.83
15.5
11.3
94.51
94.15
%
0.14
19
102
177
1623
1.68
1.75
27.4
16.0
23.37
25.06
mg/l
0.26
158
1320
22
127
1.82
1.72
3.9
2.3
64.73
64.22
ml/min/173m2
0.02
11
60
51
368
1.51
1.71
1.5
1.3
5.30
1.64
u/ml
0.39
12
104
35
233
1.61
1.66
11.4
7.1
103.26
104.54
mmol/l
0.65
35
233
140
1228
1.45
1.64
6.0
4.2
11.38
12.75
mm/h
0.54
132
1138
16
86
1.93
1.55
4.4
2.7
0.58
0.65
%
0.51
16
86
5
15
3.39
1.53
1.4
1.1
—
—
—
0
0
40
281
1.53
1.52
1.6
1.3
10.43
36.06
iu/ml
2.62
12
80
106
896
1.38
1.48
5.4
3.9
0.00
0.00
estimate
-0.00
15
198
107
906
1.38
1.48
5.4
4.0
0.00
0.00
estimate
-0.00
16
203
54
406
1.45
1.47
4.2
2.8
358.47
343.53
umol/l
0.45
47
348
108
916
1.38
1.47
5.5
4.0
0.18
1.60
estimate
0.42
17
187
7
29
2.46
1.40
1.3
1.4
—
—
—
0
0
7
29
2.46
1.40
1.3
1.4
—
—
—
0
0
9
41
2.25
1.39
1.3
1.4
229.89
311.76
mu/l
—
9
41
6
23
2.66
1.37
1.3
1.5
—
—
—
0
0
6
23
2.66
1.37
1.3
1.5
—
—
—
0
0
5
17
2.99
1.36
1.6
1.9
2.14
1.26
mmol/l
—
5
17
170
1568
1.51
1.36
24.2
16.0
80.82
79.02
ml/min/173m2
0.45
155
1455
12
61
2.03
1.36
2.8
2.0
—
—
—
0
0
6
24
2.54
1.31
1.3
1.5
—
—
—
0
0
6
24
2.54
1.31
1.3
1.5
—
—
—
0
0
6
24
2.54
1.31
1.3
1.5
—
—
—
0
0
6
24
2.54
1.31
1.3
1.5
—
—
—
0
0
15
84
1.85
1.31
1.1
1.0
—
—
—
0
0
5
19
2.67
1.22
1.2
1.1
—
—
—
0
0
162
1494
1.41
1.17
7.0
5.2
1.72
1.96
mu/l
1.92
149
1354
182
1717
1.56
1.15
16.4
11.9
28.56
25.16
u/l
1.16
177
1669
169
1573
1.43
1.13
5.6
5.0
6.15
5.95
mmol/l
1.32
154
1445
7
33
2.16
1.06
1.3
7.1
—
190.67
—
0
6
136
1232
1.31
1.03
5.9
4.2
14.87
14.84
pmol/l
0.05
123
1115
110
970
1.29
1.02
3.4
3.0
—
—
—
0
0
11
61
1.85
1.00
8.9
1.7
23.93
3.84
iu/ml
—
6
15
5
23
2.20
0.98
3.0
3.3
1.18
1.19
mmol/l
—
5
23
5
23
2.20
0.98
3.0
3.3
105.60
105.74
mmol/l
—
5
23
11
62
1.82
0.96
3.0
2.3
—
—
—
0
0
7
37
1.92
0.95
1.1
1.4
—
—
—
0
0
22
153
1.49
0.90
6.0
2.9
0.70
0.78
e6/l
0.04
22
144
10
57
1.79
0.85
6.2
2.3
—
—
—
0
0
8
46
1.77
0.83
1.8
1.5
—
—
—
0
0
10
58
1.76
0.81
2.0
1.6
—
—
—
0
0
0
24
0.00
0.79
0.0
1.2
—
7.29
—
0
18
184
1765
1.43
0.77
39.1
24.4
251.76
245.34
e9/l
0.75
178
1733
184
1766
1.43
0.76
39.1
24.4
4.42
4.47
e12/l
0.65
178
1727
34
270
1.31
0.68
2.1
1.6
—
—
—
0
0
20
147
1.40
0.64
4.0
2.6
4.05
7.58
ug/l
0.92
15
129
8
49
1.66
0.63
1.0
1.2
—
—
—
0
0
8
49
1.66
0.63
1.0
1.2
—
—
—
0
0
163
1552
1.25
0.59
8.2
6.3
41.43
39.28
mmol/mol
1.53
146
1461
6
36
1.69
0.57
1.0
1.3
—
—
—
0
0
6
40
1.51
0.52
2.0
1.4
—
—
—
0
0
14
102
1.40
0.49
1.5
1.2
40.86
162.37
u/ml
—
5
45
46
398
1.20
0.46
6.5
3.9
1.02
1.02
kg/l
2.33
35
266
0
15
0.00
0.41
0.0
1.3
—
9.67
—
0
15
0
17
0.00
0.41
0.0
1.4
—
181.04
—
0
17
5
35
1.44
0.39
1.2
1.3
—
—
—
0
0
5
35
1.44
0.39
1.0
1.1
—
3.66
—
0
5
21
170
1.26
0.39
6.4
7.1
—
—
—
0
0
5
36
1.40
0.38
1.6
1.2
0.70
0.76
nmol/l
—
5
30
11
81
1.38
0.37
1.1
1.3
—
—
—
0
0
18
144
1.27
0.37
4.2
2.5
8.63
13.29
nmol/l
1.59
18
137
6
41
1.48
0.36
1.8
1.4
—
—
—
0
0
6
43
1.41
0.35
2.7
2.4
142.50
123.94
g/l
—
6
33
6
46
1.31
0.33
1.2
1.1
—
—
—
0
0
57
518
1.14
0.32
5.9
4.0
0.00
0.01
estimate
0.50
13
182
63
580
1.12
0.29
6.5
5.4
7.31
2.82
ug/l
0.78
57
530
168
1638
1.15
0.27
6.5
5.8
2.42
2.67
mmol/l
3.73
154
1513
39
352
1.13
0.25
3.0
3.2
0.98
0.87
ug/l
0.26
28
225
5
39
1.29
0.23
4.4
2.7
9.14
8.73
pmol/l
—
5
39
5
40
1.26
0.22
1.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
24.76
—
0
5
0
10
0.00
0.21
0.0
2.4
—
—
—
0
0
0
10
0.00
0.21
0.0
2.4
—
—
—
0
0
0
10
0.00
0.21
0.0
2.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
11.10
—
0
10
0
10
0.00
0.21
0.0
2.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
7.3
—
38.55
—
0
14
6
51
1.18
0.19
1.7
1.1
—
—
—
0
0
50
466
1.10
0.19
5.2
4.6
24.78
22.15
%
0.77
36
226
15
129
1.18
0.17
1.5
2.3
—
—
—
0
0
72
690
1.07
0.14
5.7
3.8
0.55
0.02
estimate
0.74
11
160
157
1543
1.08
0.13
5.0
4.3
1.32
1.27
mmol/l
0.35
142
1417
49
512
0.94
0.10
4.8
3.5
1.36
0.17
estimate
0.65
11
151
163
1611
1.06
0.08
5.6
5.0
1.40
1.47
mmol/l
1.31
147
1487
16
146
1.10
0.08
1.7
2.4
—
—
—
0
0
18
169
1.07
0.05
2.7
3.4
—
—
—
0
0
23
240
0.95
0.03
1.8
1.4
—
—
—
0
0
70
702
1.00
0.00
1.8
1.9
1.39
1.34
mmol/l
0.22
60
581
162
1617
1.01
0.00
5.9
5.1
4.33
4.59
mmol/l
3.19
148
1502
7
79
0.88
0.00
1.4
2.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
6.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
5
52
0.96
-0.00
1.4
1.5
747.92
947.29
mu/l
—
5
39
6
66
0.91
-0.00
1.3
2.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
8.30
—
0
7
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_DISOTHUNS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_DISOTHUNS | 1.896 [1.51, 2.38] | < 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.224 |
During the follow-up period (1.1.1998 — 31.12.2019), 134 out of 486 females with G6_DISOTHUNS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_DISOTHUNS | 1.575 [1.2, 2.06] | < 0.001 |
| Birth year | 0.984 [0.97, 0.99] | 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 112 out of 418 males with G6_DISOTHUNS died.
Mortality risk
Mortality risk for people of age
years, who have G6_DISOTHUNS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.141% | 0.319% |
| 5 | 1.129% | 1.779% |
| 10 | 2.979% | 4.367% |
| 15 | 5.596% | 8.369% |
| 20 | 9.291% | 13.813% |
Relationships between endpoints
↥Index endpoint: G6_DISOTHUNS – Disorders of other and unspecified cranial nerves
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data